BMRN vs CODX · P/E 40, rev $2.85B vs rev $3.9M
Biomarin Pharmaceutical Inc (BMRN) versus Co-Diagnostics, Inc. Common Stock (CODX) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. CODX currently screens at market cap $31.4M.
Not investment advice. Open the BMRN and CODX stock pages for the full models.
Not investment advice.